Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (29074)	7/20/1999 5:46:00 PM
From: J Stone	Read Replies (1) \| Respond to of 32384

I suspect that the current price drop, although partially fueled by today's overall market dip, is due somewhat to LGND's announcing the use of ELAN cash for the Seragen purchase. The announcement dashed some people's hope that LGND was going to make some price moving announcements during the next few weeks to boost the stock price. The next news I expect from LGND will be 2nd qtr earnings. The key information for me will be the sales of ONTAK and Panretin. Both need to be significantly greater than the prior qtr. A reported loss in the $.15 - .10 range would be a strong indicator of LGND's push towards breaking even. (I'll wait on profitability until next year.) After this announcement I believe the next big announcement will be the status of the ABC trials. My question for Henry: In a double blinded-study, does the study have to be completed before looking at the data or might the data be looked at sooner? TIA Jeff